echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > How is metastatic hormone-sensitive prostate cancer treated?

    How is metastatic hormone-sensitive prostate cancer treated?

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Prostate cancer is a malignant tumor arising from the prostate.


    Astellas Pharma announced today that the European Medicines Management Agency (EMA) Committee of medicines for human use (CHMP) for XTANDI (enzalutamide) application for metastatic hormone-sensitive prostate cancer (mHSPC) adopted a positive opinion of the treatment.


    management

    If approved by the European Medicines Agency (EMA), enzalutamide will be the only MEA approved for the treatment of three different types of advanced prostate cancer-non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC Oral treatment.


    The CHMP decision is based on data from the pivotal Phase III ARCHES trial.


    The CHMP decision is based on data from the pivotal Phase III ARCHES trial.


     

    Original source:

    Original source:

    href="" target="_blank" rel="noopener">leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.